Etalocib (LY293111) sodium is an orally active leukotriene B4 (LTB4) receptor antagonist with a Ki value of 25 nM for inhibiting [3H]LTB4 binding. It exhibits an IC50 of 20 nM against LTB4-induced calcium mobilization. Additionally, Etalocib sodium can induce apoptosis.

Etalocib sodium exhibits concentration-dependent inhibition of LTB4-induced upregulation of CD11b. It acts as an extremely potent and selective antagonist of human neutrophil functions in vitro. Additionally, at concentrations of 250 and 500 nM over 24-72 hours, Etalocib sodium induces apoptosis and inhibits proliferation in human pancreatic cancer cells.

Etalocib demonstrates dose-dependent attenuation of acute leukotriene B4-induced airway obstruction, with an (ED 50 =14 μg/kg) when given intravenously and an (ED 50 =0.4 mg/kg) when administered orally. At a dosage of 10 mg/kg, it reduces lung inflammation induced by A23187 within one hour. Furthermore, daily oral administration of Etalocib at 250 mg/kg effectively suppresses the growth of human pancreatic cancer xenografts in athymic mice.